Compare Abbott Laboratories (ABT) vs Icl Group Ltd (ICL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Icl Group Ltd — how do they compare? Abbott Laboratories trades at $95.65 (market cap $166.94B), while Icl Group Ltd trades at $5.06 (market cap $6.49B). The key difference: Abbott Laboratories is far larger — about 25.7× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (3.85%). Which is the better fit depends on your goals.
| ABT | ICL | |
|---|---|---|
Market Cap | $166.94B | $6.49B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $7.23 |
52-Week Low | $82.57 | $4.80 |
Enterprise Value | $193.69B | $9.06B |
Dividend Yield | 2.63% | 3.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ICL trades at $4.95, down 1.59% on the day, with a bearish technical signal. The company reported Q1 2026 earnings of $0.11 per share, beating estimates, and announced a $0.05 dividend for H1 2026. Revenue for 2025 was $7.15B with a net income margin of 3.52%, while valuation metrics show a P/E of 24.05 and P/S of 0.88. Recent news highlights the completion of an $800 million senior notes offering to manage debt.
The outlook is mixed; strong cash flow and dividend payments provide stability, but declining profit margins and bearish analyst sentiment pose risks. Investment opportunity lies in operational improvements and potash market exposure, though investors face headwinds from raw material costs and foreign exchange volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
